{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:16:14Z","timestamp":1787030174288,"version":"build-2736575974"},"reference-count":22,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute (KHIDI) under the Ministry of Health &amp; Welfare, Republic of Korea","doi-asserted-by":"publisher","award":["HQ22C0057"],"award-info":[{"award-number":["HQ22C0057"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EuBiologics Co., LTD","award":["HQ22C0057"],"award-info":[{"award-number":["HQ22C0057"]}]},{"name":"Division of Intramural Research (DIR)","award":["HQ22C0057"],"award-info":[{"award-number":["HQ22C0057"]}]},{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","award":["HQ22C0057"],"award-info":[{"award-number":["HQ22C0057"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: We previously reported an interim safety and immunogenicity analysis of a Phase 3 trial in the Philippines of the EuCorVac-19 (ECV-19) COVID-19 vaccine with the COVISHIELDTM (CS) comparator (ClinicalTrials.gov identifier NCT05572879). Here, we present full-year humoral immunogenicity analysis. Methods: Healthy adults over 18 years of age received two injections of ECV-19 or CS vaccines, with 4 weeks between prime and boost. Analysis was carried out in individuals with immunogenicity measurements available at all 4 timepoints (weeks 0, 6, 30, and 56; n = 535 for ECV-19 and n = 260 for CS). Results: 2 weeks after boosting (week 6), ECV-19 elicited higher median anti-RBD IgG (1512 vs. 340 BAU\/mL, p &lt; 0.001) and neutralizing antibodies (1280 vs. 453 median microneutralization (MN) titer, p &lt; 0.001) compared to CS. Anti-RBD IgG remained higher for ECV-19 compared to CS through week 30 (412 vs. 238 BAU\/mL, p &lt; 0.001) and 56 (425 vs. 260 BAU\/mL, p &lt; 0.001). MN titers remained higher for ECV-19 compared to CS through week 30 (640 vs. 453, p &lt; 0.001) and 56 (453 vs. 320, p &lt; 0.001). Correlation between anti-RBD IgG and neutralization titers persisted throughout the study. Women generally exhibited greater antibody responses than men. In the first six months following immunization, the ECV-19 group had a median antibody half-life of 80 days for anti-RBD IgG and 112 days for MN titer. In the subsequent six months, antibody half-life increased to 237 days for anti-RBD IgG and 168 days for MN titer. Conclusions: Following initial prime-boost vaccination, ECV-19 maintained higher anti-RBD IgG and neutralizing antibody titers relative to the CS comparator over a full-year period.<\/jats:p>","DOI":"10.3390\/vaccines13080776","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:45:18Z","timestamp":1753173918000},"page":"776","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-884X","authenticated-orcid":false,"given":"Jonathan F.","family":"Lovell","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, Buffalo, NY 14260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-2432","authenticated-orcid":false,"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong Ok","family":"Baik","sequence":"additional","affiliation":[{"name":"EuBiologics, R&D Center, EuBiologics Co., Ltd., Seoul 06778, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chankyu","family":"Lee","sequence":"additional","affiliation":[{"name":"EuBiologics, R&D Center, EuBiologics Co., Ltd., Seoul 06778, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoungJin","family":"Choi","sequence":"additional","affiliation":[{"name":"EuBiologics, R&D Center, EuBiologics Co., Ltd., Seoul 06778, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yoon","family":"Lee","sequence":"additional","affiliation":[{"name":"EuBiologics, R&D Center, EuBiologics Co., Ltd., Seoul 06778, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole A.","family":"Long","sequence":"additional","affiliation":[{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-4460","authenticated-orcid":false,"given":"Michelle","family":"Ylade","sequence":"additional","affiliation":[{"name":"National Institutes of Health, University of the Philippines Manila, Manila 1000, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxas","family":"Lee-Llacer","sequence":"additional","affiliation":[{"name":"Bicol Regional Training and Teaching Hospital, Albay 4501, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"De Asis","sequence":"additional","affiliation":[{"name":"Norzel Medical & Diagnostic Clinic, Cebu City 6000, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitzi","family":"Trinidad-Aseron","sequence":"additional","affiliation":[{"name":"University of Perpetual Help System DALTA, Manila 1740, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Manuel Ranola","sequence":"additional","affiliation":[{"name":"St John Hospital Inc., Naga 4400, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Zoleta De Jesus","sequence":"additional","affiliation":[{"name":"Silang Specialists Medical Center, Cavite 4118, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Her","sequence":"additional","affiliation":[{"name":"EuBiologics, R&D Center, EuBiologics Co., Ltd., Seoul 06778, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14760584.2024.2331065","article-title":"The durability of vaccine-induced protection: An overview","volume":"23","author":"Vashishtha","year":"2024","journal-title":"Exp. Rev. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123610","DOI":"10.1016\/j.lfs.2025.123610","article-title":"Efficacy and limitations of SARS-CoV-2 vaccines\u2014A systematic review","volume":"371","author":"Azeem","year":"2025","journal-title":"Life Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Matsumoto, N., Sasaki, A., Kadowaki, T., Mitsuhashi, T., Takao, S., and Yorifuji, T. (2024). Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55245-9"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e27211","DOI":"10.1016\/j.heliyon.2024.e27211","article-title":"Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy","volume":"10","author":"Choi","year":"2024","journal-title":"Heliyon"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-024-01846-9","article-title":"Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: A prospective longitudinal study","volume":"9","author":"Liu","year":"2024","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gonzales, M., Dans, L.F., Tan-Lim, C.S.C., Uy, E., Cutiongco-Dela Paz, E., Sulit, M.V.V., Alejandria, M.M., Lansang, M.A.D., Dans, A.L., and Dator, M.A. (2023). Durability and extent of protection of SARS-CoV-2 antibodies among patients with COVID-19 in Metro Manila, Philippines. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1190093"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s41182-022-00468-7","article-title":"SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: A repeated cross-sectional analysis","volume":"50","author":"Malijan","year":"2022","journal-title":"Trop. Med. Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106260","DOI":"10.1016\/j.jinf.2024.106260","article-title":"Indirect effectiveness of a novel SARS-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis","volume":"89","author":"Aziz","year":"2024","journal-title":"J. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comp. Struct. Biotechnol. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2005637","DOI":"10.1002\/adma.202005637","article-title":"SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lovell, J.F., Baik, Y.O., Choi, S.K., Lee, C., Lee, J.-Y., Miura, K., Huang, W.-C., Park, Y.-S., Woo, S.-J., and Seo, S.H. (2022). Interim analysis from a phase 2 randomized trial of EuCorVac-19: A recombinant protein SARS-CoV-2 RBD nanoliposome vaccine. BMC Med., 20.","DOI":"10.1186\/s12916-022-02661-1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nchem.2236","article-title":"Functionalization of cobalt porphyrin\u2013phospholipid bilayers with his-tagged ligands and antigens","volume":"7","author":"Shao","year":"2015","journal-title":"Nat. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e29927","DOI":"10.1002\/jmv.29927","article-title":"Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines","volume":"96","author":"Lovell","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of novel vaccine vectors: Chimpanzee adenoviral vectors","volume":"14","author":"Guo","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijid.2023.11.004","article-title":"One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects","volume":"138","author":"Lovell","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Marchevsky, N.G., Li, G., Aley, P., Costa Clemens, S.A., Barrett, J.R., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E., Dold, C., and Felle, S. (2022). An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. eBioMedicine, 81.","DOI":"10.1016\/j.ebiom.2022.104128"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/infdis\/jiab314","article-title":"COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men","volume":"224","author":"Demonbreun","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e14286","DOI":"10.1111\/eci.14286","article-title":"Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies","volume":"54","author":"Barosa","year":"2024","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Focosi, D. (2023). From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses. Vaccines, 11.","DOI":"10.3390\/vaccines11010109"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/776\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:40Z","timestamp":1760033620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["vaccines13080776"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13080776","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}